Skip to content

Insmed INSM Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Gross margin308.5%-0.9pp309.3%-4.5pp313.9%+5.8pp308.1%+4.8pp
Operating margin-974.4%-36.5pp-937.8%-15.9pp-921.9%-207pp-715%+58.8pp
Net margin-1,001.1%-16.9pp-984.3%-10.4pp-973.8%-193pp-781%+104pp
EBITDA margin-962.5%-35.3pp-927.2%-13.1pp-914.1%-211pp-703%+50.0pp
Free cash flow margin-787.6%-41.8pp-745.8%-26.5pp-719.3%-49.9pp-669.4%+103pp
Returns
Return on assets-229.8%-19.0pp-210.9%-1.5pp-209.4%-54.6pp-154.7%+9.4pp
Return on invested capital-814.9%+233pp-1,047.6%-315pp-732.7%-189pp-544.1%+128pp
Efficiency
Asset turnover0.9×+0.1×0.9×0.0×0.9×+0.1×0.8×0.0×
Inventory turnover+0.4×3.6×+0.3×3.3×+0.1×3.3×-0.1×
Liquidity
Current ratio21×+4.7×16.3×-3.7×20×-3.3×23.3×-8.0×
Quick ratio19.7×+4.4×15.2×-3.2×18.5×-2.8×21.3×-7.6×
Cash ratio7.7×+0.3×7.4×-5.3×12.8×-3.7×16.4×-10.7×
Leverage
Debt-to-equity13.4×
Debt-to-assets1.4×-1.4×2.8×-0.6×3.4×+0.4×3.1×+1.0×
Interest coverage-51.8×-14.0×-37.8×+2.6×-40.4×+19.4×-59.8×-20.8×
Per Share
Book value per share$15.33+833%$1.64+128%-$5.85-417%$1.84-87.5%
Valuation
Market capitalization$101.48B+170%$37.52B+179%$13.46B+25.9%$10.69B-21.1%
Enterprise value$101.83B+160%$39.24B+150%$15.68B+31.2%$11.95B-7.1%
Price / sales216.1×+106×109.6×+61.8×47.9×+0.6×47.3×-30.4×
Price / book237.8×
EV / sales216.9×+102×114.7×+59.0×55.7×+2.8×52.9×-20.8×
Free cash flow yield-15.6%+16.6pp-32.3%+29.6pp-61.9%-4.7pp-57.2%-16.9pp
Earnings yield-19.8%+22.3pp-42.1%+41.0pp-83.1%-16.7pp-66.5%-20.2pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Insmed's profit margins?
Insmed (INSM) runs a 81.8% gross margin and a -140.6% operating margin, with a -144.4% net margin.
Where do Insmed's ratios come from?
Every ratio is computed from Insmed's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.